{"id":"azd3759","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3623290","moleculeType":"Small molecule","molecularWeight":"459.91"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD3759 works by selectively inhibiting the activity of the epidermal growth factor receptor (EGFR), a protein that plays a key role in the development and progression of certain types of cancer. By blocking EGFR, AZD3759 can help slow or stop the growth of cancer cells.","oneSentence":"AZD3759 is a small molecule inhibitor of the EGFR pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:19.877Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07361705","phase":"PHASE1","title":"Zorifertinib With Osimertinib for NSCLC With Meningeal Progression","status":"NOT_YET_RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2026-01-31","conditions":"Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment","enrollment":42},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT03574402","phase":"PHASE2","title":"Phase II Umbrella Study Directed by Next Generation Sequencing","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2018-07-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":400},{"nctId":"NCT03360929","phase":"PHASE1, PHASE2","title":"Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759","status":"COMPLETED","sponsor":"LYZZ Alpha Holding Ltd","startDate":"2017-10-30","conditions":"Non Small Cell Lung Cancer","enrollment":15},{"nctId":"NCT02228369","phase":"PHASE1","title":"Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-05","conditions":"EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD3759","genericName":"AZD3759","companyName":"Guangdong Association of Clinical Trials","companyId":"guangdong-association-of-clinical-trials","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD3759 is a small molecule inhibitor of the EGFR pathway. Used for Non-small cell lung cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}